Mission
Turn cancer immunotherapy resistance into therapeutic and diagnostic assets.
MIORG uses patient-derived tumor samples and state-of-the-art multiomic approaches to identify biomarkers, therapeutic targets, and resistance mechanisms that can be converted into practical oncology assets.
Our discovery model begins with clinically relevant human tumor biology, then moves toward target validation, therapeutic design, diagnostic development, and pharma partnering.
Turn cancer immunotherapy resistance into therapeutic and diagnostic assets.
Build a Finnish reverse translational oncology company with global relevance in precision immunotherapy.
Many patients still fail to benefit from immune checkpoint therapy because resistance remains insufficiently actionable.
MIORG is built around a patient-centric discovery model: clinically relevant biospecimens, multiomic profiling, systems immunology, and functional validation are integrated to discover mechanisms of therapeutic response and resistance. The goal is not discovery for its own sake, but the creation of actionable programs that can support rational combinations for existing immunotherapies, biomarker-guided prognostic tests, and strategic partnerships.
MIORG’s approach is designed to make target discovery more biologically grounded, functional validation more clinically relevant, and therapeutic development more partnership-ready.